[II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Michinori
M
Ogura
D000367:Age Factors; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*
D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride